|Day Low/High||4.25 / 4.40|
|52 Wk Low/High||2.57 / 8.74|
The most recent short interest data was recently released for the 10/14/2016 settlement date, and Titan Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 12.68 "days to cover" versus the median component at 6.24. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Here are Monday's top research calls, including upgrades for American Eagle, Mattel and Tesaro, and new coverage of Netflix.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CVRR, TTNP, WMS Downgrades: DAR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Titan Pharmaceuticals Inc , where a total of 4,278 contracts have traded so far, representing approximately 427,800 underlying shares. That amounts to about 262.5% of TTNP's average daily trading volume over the past month of 163,000 shares.
Results Demonstrate the Superiority of Probuphine for Abstinence from Opioids for Patients over Six Months
Patients and Providers Have a New Option to Combat Opioid Dependence
These stocks trading for less than $10 a share look ready to break out and trade higher from current levels.
Titan Pharmaceuticals (TTNP) stock is climbing after the FDA's Psychopharmacologic Drugs Advisory Committee voted in favor of approving the company's treatment for opioid addiction.
These under-$10 biotech stocks are within range of triggering major breakout trades.
Titan and its partner will resubmit Probuphine for FDA approval later this year.
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals,...
FDA find much at fault with Titan's implantable therapy for opioid dependence.